Tyrosine Kinase Inhibitor

In this video, Erminia Massarelli, MD, PhD, MS, co-director of the lung cancer and thoracic oncology program, and associate professor in the department of medical oncology and therapeutics research at City of Hope Cancer Center in Duarte, California, discusses treatment variations for rarer mutations such as EGFR exon 20 insertions.

Erminia Massarelli, MD, PhD, MS, co-director of the lung cancer and thoracic oncology program, and associate professor in the department of medical oncology and therapeutics research at City of Hope Cancer Center in Duarte, California, spoke with Healio about treatment approaches for EGFR 19 deletions and EGFR L858R in small cell lung cancer.

In this video, Erminia Massarelli, MD, PhD, MS, co-director of the lung cancer and thoracic oncology program, and associate professor in the department of medical oncology and therapeutics research at City of Hope Cancer Center in Duarte, California, highlights treatment options for EGFR-mutated lung cancer.

In the last two decades, the approval of multiple tyrosine kinase inhibitors for chronic myeloid leukemia has vastly improved the treatment landscape for patients.

Targeted therapies in HER2-positive breast cancer are integral to the success of treatment outcomes in this patient population.

In this video, Alexander Edward Perl, MD, MS, spoke with Healio about a study assessing the outcome of patients with acute myeloid leukemia who received gilterintib with prior midostaurin or sorafenib therapy.

The FDA approved mobocertinib for treatment of certain patients with non-small cell lung cancer.

In this video, John C. Byrd, MD, a professor at The Ohio State University, discussed the study he presented at ASCO21 that showed progression-free survival rates were equal among patients with CML treated with acalabrutinib vs. ibrutinib.

Tyrosine kinase inhibitor-sensitive genomic aberrations, unresected tumors and not smoking were associated with increased treatment failure in non-small cell lung cancer, according to a presentation at the virtual ASCO annual meeting.

In this video, Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology at the University of Pennsylvania Perelman School of Medicine, spoke with Healio about research on deucravacitinib presented at AAD VMX 2021.